Compare CLF & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLF | ELVN |
|---|---|---|
| Founded | 1847 | 2016 |
| Country | United States | United States |
| Employees | 25000 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.2B |
| IPO Year | 2006 | 2020 |
| Metric | CLF | ELVN |
|---|---|---|
| Price | $12.77 | $40.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $12.60 | ★ $73.67 |
| AVG Volume (30 Days) | ★ 15.0M | 1.5M |
| Earning Date | 10-19-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,610,000,000.00 | N/A |
| Revenue This Year | $15.97 | N/A |
| Revenue Next Year | $4.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $14.79 |
| 52 Week High | $16.70 | $62.32 |
| Indicator | CLF | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 23.68 |
| Support Level | $11.78 | $38.58 |
| Resistance Level | $12.81 | $43.05 |
| Average True Range (ATR) | 0.55 | 1.84 |
| MACD | 0.10 | -0.34 |
| Stochastic Oscillator | 82.43 | 16.51 |
Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.